Prudential Securities analyst Joseph Edelman on Tuesdaylopped 10 cents off his 1993 earnings estimate for Amgen Inc.to reflect expected higher research and development costs. Helowered his estimate to $2.40 from $2.50. He continues to rateAmgen a "buy."

(c) 1997 American Health Consultants. All rights reserved.

No Comments